Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatitis c | D006526 | — | B19.2 | 4 | 12 | 31 | 14 | 20 | 77 |
Hepatitis | D006505 | — | K75.9 | 3 | 11 | 32 | 14 | 18 | 74 |
Hepatitis a | D006506 | EFO_0007305 | B15 | 3 | 10 | 28 | 12 | 17 | 66 |
Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 3 | 9 | 26 | 12 | 19 | 65 |
Chronic hepatitis | D006521 | — | K73.9 | 3 | 3 | 7 | 2 | 1 | 15 |
Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 6 | 4 | 1 | — | 13 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 2 | 6 | 1 | — | 8 |
Fibrosis | D005355 | — | — | — | 2 | 4 | 1 | — | 6 |
Hepatitis b | D006509 | — | — | — | — | 5 | 1 | — | 6 |
Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | 4 | 1 | 1 | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Melanoma | D008545 | — | — | 8 | 5 | 3 | — | 4 | 18 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | 5 | 1 | — | — | 6 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 2 | 2 | 1 | — | — | 5 |
Coinfection | D060085 | — | — | — | 1 | 1 | — | — | 2 |
Carcinoma | D002277 | — | C80.0 | 1 | 1 | 1 | — | — | 2 |
Recurrence | D012008 | — | — | — | 1 | 1 | — | — | 2 |
Menopause | D008593 | EFO_0003922 | N95 | — | — | 1 | — | — | 1 |
Neoadjuvant therapy | D020360 | — | — | — | — | 1 | — | — | 1 |
Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | 1 | — | — | 1 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 1 | 3 | — | — | — | 4 |
Neoplasms | D009369 | — | C80 | 2 | 1 | — | — | — | 3 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 3 | 2 | — | — | — | 3 |
Myeloid leukemia | D007951 | — | C92 | — | 3 | — | — | — | 3 |
Communicable diseases | D003141 | — | — | — | 2 | — | — | — | 2 |
Hiv | D006678 | — | O98.7 | 1 | 1 | — | — | — | 2 |
Cutaneous malignant melanoma | D000096142 | — | — | — | 1 | — | — | 1 | 2 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | — | 1 |
Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | — | 1 | — | — | — | 1 |
Cholangiocarcinoma | D018281 | — | C22.1 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | — | — | — | — | 1 |
Aids-related opportunistic infections | D017088 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | — | 1 | 1 |
Intravenous substance abuse | D015819 | — | — | — | — | — | — | 1 | 1 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | — | — | — | — | 1 | 1 |
Lymphoma | D008223 | — | C85.9 | — | — | — | — | 1 | 1 |
Follicular lymphoma | D008224 | — | C82 | — | — | — | — | 1 | 1 |
Drug common name | Albinterferon alfa-2b |
INN | albinterferon alfa-2b |
Description | Albinterferon (alb-IFN, trade name Albuferon) is a recombinant fusion protein drug consisting of interferon alpha (IFN-α) linked to human albumin. Conjugation to human albumin prolongs the half-life of the IFN-α to about 6 days, allowing to dose it every two to four weeks.
|
Classification | Protein |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2107842 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 4DVS4AG4DF (ChemIDplus, GSRS) |